Pfizer stock: New products lift 2026 outlook after Q3 beat

Published on 11/07/2026 at 11:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Pfizer stock enters the weekend with newer products offsetting weaker COVID sales. Pipeline execution remains central to the investment case.

Pfizer enters the weekend with stronger pipeline signals

Newly launched and acquired products grew 32 percent operationally in the third quarter.
Pfizer raised its 2026 revenue outlook to 62.0 billion to 64.0 billion US dollars.
ELREXFIO met the primary endpoint in a Phase 3 multiple myeloma study, while overall-survival data remain immature.

Pfizer Inc., US7170811035, Illustration mit AI erstellt.

Pfizer reported third-quarter results on Tuesday, November 3, and raised its 2026 financial outlook as newer products offset continued weakness in its COVID portfolio. CNBC reported that revenue of 16.58 billion US dollars and adjusted earnings of 0.87 US dollars per share exceeded analyst expectations.

The company now expects full-year revenue of 62.0 billion to 64.0 billion US dollars, compared with its previous range of 60.5 billion to 62.5 billion US dollars. Adjusted earnings guidance increased to 2.95 to 3.05 US dollars per share from 2.80 to 3.00 US dollars.

Outlook rises on newer products

Pfizer said newly launched and acquired products contributed 3.8 billion US dollars in the quarter and grew 32 percent operationally. Eliquis revenue rose 25 percent to 2.52 billion US dollars, while Padcev generated 720 million US dollars. Total quarterly revenue was broadly flat year over year, highlighting the continuing transition away from pandemic-era COVID products.

CNBC also reported a one-time 650 million US dollar charge tied to Pfizer's licensing and collaboration agreement with Innovent Biologics. The charge reduced adjusted earnings by 0.10 US dollars per share, making the adjusted guidance range particularly relevant when assessing underlying operating momentum.

Pipeline data add a second catalyst

On October 27, Pfizer announced that the Phase 3 MagnetisMM-32 study of ELREXFIO met its primary progression-free-survival endpoint in adults with relapsed or refractory multiple myeloma. Pfizer said more than 75 percent of patients receiving ELREXFIO had not experienced disease progression or death at the analysis, with estimated progression-free survival of 68 percent at 18 months.

The company's announcement also said overall-survival data remain immature and that Pfizer plans to submit the findings to global health authorities. For investors, the result supports the oncology pipeline, but regulatory review, further follow-up and the medicine's safety profile remain important next steps.

Pfizer stock traded at 26.32 euros on Lang & Schwarz at 11:17 CET on Saturday, November 7. Investors can follow the real-time quote of Pfizer stock.